Clearside Biomedical (NASDAQ:CLSD) Receives New Coverage from Analysts at Oppenheimer

Stock analysts at Oppenheimer started coverage on shares of Clearside Biomedical (NASDAQ:CLSD) in a report issued on Tuesday, Marketbeat reports. The firm set an “outperform” rating and a $5.00 price target on the stock. Oppenheimer’s price objective points to a potential upside of 313.22% from the company’s previous close.

Several other brokerages have also recently commented on CLSD. JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of Clearside Biomedical in a report on Wednesday, March 13th. Wedbush reaffirmed an “outperform” rating and set a $4.00 target price (down from $5.00) on shares of Clearside Biomedical in a research report on Wednesday, March 13th. Needham & Company LLC reiterated a “buy” rating and issued a $4.00 price target on shares of Clearside Biomedical in a research report on Monday, May 13th. StockNews.com cut Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Friday, May 10th. Finally, HC Wainwright reduced their price objective on shares of Clearside Biomedical from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Monday, May 13th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $4.60.

Clearside Biomedical Trading Down 3.2 %

Shares of NASDAQ:CLSD opened at $1.21 on Tuesday. The firm’s 50 day moving average is $1.28 and its two-hundred day moving average is $1.33. The firm has a market capitalization of $90.42 million, a P/E ratio of -2.20 and a beta of 2.36. Clearside Biomedical has a 52 week low of $0.65 and a 52 week high of $2.12.

Clearside Biomedical (NASDAQ:CLSD) last announced its earnings results on Thursday, May 9th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The business had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.98 million. During the same quarter in the prior year, the firm earned ($0.15) earnings per share. Analysts predict that Clearside Biomedical will post -0.63 EPS for the current year.

Institutional Investors Weigh In On Clearside Biomedical

Several hedge funds have recently bought and sold shares of CLSD. SG Americas Securities LLC purchased a new position in Clearside Biomedical during the 1st quarter valued at about $49,000. International Assets Investment Management LLC acquired a new stake in shares of Clearside Biomedical during the first quarter worth approximately $57,000. Vanguard Group Inc. grew its position in Clearside Biomedical by 14.5% during the first quarter. Vanguard Group Inc. now owns 2,490,796 shares of the company’s stock valued at $3,811,000 after purchasing an additional 314,480 shares in the last quarter. Finally, Rosalind Advisors Inc. acquired a new position in Clearside Biomedical in the 1st quarter valued at approximately $3,967,000. 18.75% of the stock is owned by hedge funds and other institutional investors.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.